SCHEMBL4942383

SCHEMBL4942383

COC(=O)C1(c2cccc(F)c2)CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
LMNA P02545 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
MEN1 O00255 1/20 0.50
TP53 P04637 1/20 0.50
KMT2A Q03164 1/20 0.50
HDAC4 P56524 3/20 0.48
SLC6A4 P31645 2/20 0.48
SLC6A3 Q01959 2/20 0.48
P2RX7 Q99572 1/20 0.46
SLC6A2 P23975 1/20 0.44
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
CHRM3 P20309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427933 0.98 LMNA (0.55) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL29924430 0.94 TSHR (0.49) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL29149857 0.94 TSHR (0.49) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL1428212 0.88 TSHR (0.46) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL23163696 0.87 TSHR (0.47) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL13887004 0.85 TSHR (0.42) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL4830534 0.84 HDAC4 (0.43) TSHRLMNANPSR1TDP1ALDH1A1
SCHEMBL2848806 0.83 HDAC4 (0.49) TSHRLMNANPSR1TDP1HDAC4
SCHEMBL29705606 0.83 HDAC4 (0.49) TSHRLMNANPSR1TDP1HDAC4
SCHEMBL17147282 0.83 HDAC4 (0.68) TSHRLMNANPSR1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419999-B2 Gamma lactams as prostaglandin agonists and use thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-09-02 US disclosed
EP-1556347-A4 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2006-08-09 EP disclosed
US-20050288357-A1 Gamma lactams as prostaglandin agonists and use thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-12-29 US disclosed
EP-1556347-A2 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2005-07-27 EP disclosed
WO-2003103604-A2 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288357-A1 Gamma lactams as prostaglandin agonists and use thereof PGF, HPGDS, PTGIS TSHR 2081/4885LMNA 1060/4885NPSR1 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.